Analysis of remodeling and resorption rate of OsteoAMP bone allograft in LeFort midface reconstruction and malar augmentation

Abstract

Osteo allogenic morphogenetic protein (OsteoAMP) is an allogenic morphogenetic protein derived from bone allograft through a novel tissue processing technique. In this report, we document a surgical case that included LeFort advancement and malar augmentation with OsteoAMP. Postoperatively, the patient demonstrated a persistent volume of graft material, as viewed radiographically after 4 months by an expert radiologist, that is less than expected, compared to other demineralized bone matrix allograft products [10]. This was observed both clinically (in the form of subjective malar fullness) and radiographically on non-contrast CT imaging (the estimated volume of the bone graft on the followup CT was measured as 3400 mm3 compared to 3970 mm3 on the postoperative CT). The patient then required an additional procedure to recontour the excessive malar graft material, which on immunohistochemical analysis, was negative for CD65 and TARP, again confirming a decreased resorption rate. This case suggests that OsteoAMP undergoes decreased rates of remodeling and resorption, over a 3-month period, as analyzed by expert radiology and pathology specialists. This may help inform bone graft treatment plan decisions, including graft material selection and graft volume.

Keywords

• OsteoAMP
• Bone allograft
• Bone graft substitute. LeFort midface reconstruction. malar augmentation